Related Experiment Videos
Vaccination for vivax malaria: targeting the invaders
Spencer D Polley1, Louisa McRobert, Colin J Sutherland
1Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel St, London WC1E7HT, UK.
Trends in Parasitology
|May 6, 2006
Summary
Developing a Plasmodium vivax vaccine is crucial. Recombinant merozoite surface protein 1 subunits show promise by binding to reticulocytes, aiding vaccine candidate validation.
Area of Science:
- Malariology
- Vaccinology
- Parasitology
Background:
- Surface-exposed antigens of the malaria parasite Plasmodium vivax are key targets for vaccine development.
- Antigens with essential functions, disruptable by antibodies, are most promising for effective malaria vaccines.
Purpose of the Study:
- To discuss pre-clinical analyses for validating Plasmodium vivax vaccine candidate molecules.
- To highlight the significance of binding reticulocytes as a pre-clinical validation step.
Main Methods:
- Enzyme-linked immunosorbent assays (ELISAs) were used to test antigen binding.
- Two recombinant protein subunits of Plasmodium vivax merozoite surface protein 1 (MSP-1) were analyzed.
Main Results:
- The recombinant MSP-1 subunits demonstrated binding to reticulocytes.
- This binding indicates potential for antibody-mediated disruption of parasite function.
Conclusions:
- Pre-clinical validation using methods like reticulocyte binding assays is vital for Plasmodium vivax vaccine candidates.
- Challenges in primate model use and trial material costs necessitate robust pre-clinical assessments.